Astrazeneca (AZN)

 

AZN Share PerformanceMore

52 week high5,520 22/06/17
52 week low3,996 06/12/16
52 week change 208 (4.20%)
4 week volume42,364,590 20/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Credit Suisse issues a broker note on AstraZeneca PLC

Credit Suisse today upgrades its investment rating on AstraZeneca PLC (LON:AZN) to outperform (from neutral) and rai...

Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price tar...

A debt warning and short selling

If hedge funds smell blood they'll attack vulnerable companies for profit. David Brenchley reveals this fund's short positio...

Broker Forecast - HSBC issues a broker note on AstraZeneca PLC

HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 4150p (f...

AZN cancer drug granted breakthrough therapy designation

AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation fo...

FDA grants Tagrisso BTD for 1st-line EGFR nsclc

RNS Number: 0020T AstraZeneca PLC 09 October 2017 9 October 2017 07:00 BST TAGRISSO GRANTED BREAKTHROUGH THERAPY DESIGNATION BY US FDA FOR THE 1ST-LINE TREATMENT OF PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER Designation based on positive Phase III FLAURA trial results Sixth...

Total Voting Rights

RNS Number: 4425S AstraZeneca PLC 02 October 2017 02 October 2017 15:00 BST Transparency Directive Voting Rights and Capital The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 September 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,265,913,842...

Director/PDMR Shareholding

RNS Number: 8473R AstraZeneca PLC 26 September 2017 26 September 2017 12:00 BST TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company's American Depositary Shar...

Latest discussion posts More

  • EU approval in the pipeline

    The European Medicines Agency accepts for review AstraZeneca's (NYSE:AZN) marketing application seeking approval for Imfinzi (durvalumab) for the treatment of patients with ...
    9-Oct-2017
    Proverbs 26 vs 5
  • AZN cancer drug granted breakthrough therapy designation

    AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation for Tagrisso (osimertinib) for the first-line treatment of ...
    9-Oct-2017
    Proverbs 26 vs 5
  • Re: quiet

    up another 10+%
    21-Sep-2017
    nick2name

Users' HoldingsMore

Users who hold Astrazeneca also hold..
GLAXOSMITHKLINE46%
BP35%
VODAFONE GRP.35%
NATIONAL GRID35%
RDS 'B'33%

Codes & Symbols

ISINGB0009895292
SymbolsAZN, LSE:AZN, AZN.L, AZN:LN, LON:AZN, XLON:AZN